- freely available
Tumor-Associated Glycans and Immune Surveillance
AbstractChanges in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.
Share & Cite This Article
Monzavi-Karbassi, B.; Pashov, A.; Kieber-Emmons, T. Tumor-Associated Glycans and Immune Surveillance. Vaccines 2013, 1, 174-203.View more citation formats
Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. Tumor-Associated Glycans and Immune Surveillance. Vaccines. 2013; 1(2):174-203.Chicago/Turabian Style
Monzavi-Karbassi, Behjatolah; Pashov, Anastas; Kieber-Emmons, Thomas. 2013. "Tumor-Associated Glycans and Immune Surveillance." Vaccines 1, no. 2: 174-203.
Notes: Multiple requests from the same IP address are counted as one view.